Tearable packages for pharmaceutical product and method
    1.
    发明公开
    Tearable packages for pharmaceutical product and method 审中-公开
    ZerreißbareVerpackungenfürpharmazeutische Produkte und Verfahren

    公开(公告)号:EP2105389A1

    公开(公告)日:2009-09-30

    申请号:EP09156185.2

    申请日:2009-03-25

    申请人: MonoSol RX LLC

    IPC分类号: B65D75/58

    CPC分类号: B65D75/5805 B65D2215/04

    摘要: An aspect of the invention provides a tearable package (10) for a pharmaceutical product (40) including: (i) a first layer (12) including a sheet of flexible material; (ii) a second layer (14) including a sheet of flexible material; the layers being overlaid and fused together at a perimetrical sealing region (20), the fused layers (12,14) defining a cavity (16) therebetween for the storage of the pharmaceutical product (40); wherein one of the layers (12) has a discontinuous region (30) in the sealing region (20); and wherein the package (10) may be folded through the discontinuous region (30) to be torn such that the pharmaceutical contents may be removed.

    摘要翻译: 本发明的一个方面提供了一种用于药物产品(40)的可撕裂包装(10),包括:(i)包括柔性材料片的第一层(12) (ii)包括柔性材料片的第二层(14); 所述层在周边密封区域(20)处被覆盖并熔合在一起,所述熔融层(12,14)在其间限定用于储存药品(40)的空腔(16)。 其中所述层(12)中的一个在所述密封区域(20)中具有不连续区域(30); 并且其中所述包装(10)可以通过所述不连续区域(30)折叠以被撕裂,使得可以去除所述药物内容物。

    Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
    3.
    发明公开
    Uniform films for rapid dissolve dosage form incorporating taste-masking compositions 有权
    Einheitliche Filme als schnellauflösendeVerabreichungsformen enthaltend geschmacksmaskierenden Stoff

    公开(公告)号:EP2332523A1

    公开(公告)日:2011-06-15

    申请号:EP11157819.1

    申请日:2002-10-11

    申请人: MonoSol RX LLC

    IPC分类号: A61K9/70 A61K9/00 A61K9/16

    摘要: A thin film drug delivery composition includes (i) a flowable water-soluble film forming matrix; (ii) a particulate bioeffecting agent uniformly stationed therein; and (iii) a taste-masking agent coated or intimately associated with the particulate to provide taste-masking of the bioeffecting agent. The combined particulate and taste-masking agent have a particle size of 200 microns or less and the flowable water-soluble film forming matrix is capable of being dried without loss of uniformity in the stationing of the particulate bioeffecting agent therein. The combined particulate and taste-masking agent have a particle size of 150 microns or less, for example 100 microns or less. Moreover, the flowable water-soluble film forming matrix is formable into a dry film of less than about 380 microns in thickness, for example less than about 250 microns in thickness.

    摘要翻译: 薄膜药物递送组合物包括(i)可流动的水溶性成膜基质; (ii)均匀驻留在其中的颗粒状生物影响剂; 和(iii)与颗粒包衣或密切相关的掩味剂,以提供生物效应剂的掩味。 组合的颗粒和掩味剂具有200微米或更小的粒度,并且可流动的水溶性成膜基质能够在其中颗粒生物效应剂的驻留中不损失均匀性的情况下进行干燥。 组合的颗粒和掩味剂的粒度为150微米或更小,例如100微米或更小。 此外,可流动的水溶性成膜基质可以形成为厚度小于约380微米,例如小于约250微米厚的干膜。

    Polyethylene oxide-based films and drug delivery systems made herefrom
    4.
    发明公开
    Polyethylene oxide-based films and drug delivery systems made herefrom 审中-公开
    基于聚环氧乙烷的膜和由此制成的药物递送系统

    公开(公告)号:EP2716284A2

    公开(公告)日:2014-04-09

    申请号:EP13189513.8

    申请日:2004-05-28

    申请人: MonoSol RX LLC

    IPC分类号: A61K9/70 A61K47/34 A61K47/38

    摘要: The invention relates to the film products and methods of their preparation that demonstrate a non-self-aggregating uniform heterogeneity. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. The films contain a polymer component, which includes polyethylene oxide optionally blended with hydrophilic cellulosic polymers. Desirably, the films also contain a pharmaceutical and/or cosmetic active agent with no more than a 10% variance of the active agent pharmaceutical and/or cosmetic active agent per unit area of the film.

    摘要翻译: 本发明涉及显示非自聚集均匀异质性的膜产品及其制备方法。 理想的是,这些薄膜在水中崩解并且可以通过受控的干燥过程或维持薄膜所需的均匀性的其他过程形成。 该膜含有聚合物组分,其包括任选地与亲水性纤维素聚合物共混的聚环氧乙烷。 理想的是,所述膜还含有药物和/或美容活性剂,其每单位面积的膜具有不超过10%的活性剂药物和/或美容活性剂变化。

    Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
    6.
    发明公开
    Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom 审中-公开
    非自组装均匀异质性的薄膜,因此制成的药物递送系统

    公开(公告)号:EP2428206A1

    公开(公告)日:2012-03-14

    申请号:EP11192578.0

    申请日:2004-01-30

    申请人: MonoSol RX LLC

    IPC分类号: A61K9/70 F26B13/10 A61K9/00

    摘要: The invention relates to film products containing desired levels of active components and methods of their preparation. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. Desirably, the films may be exposed to temperatures above that at which the active components typically degrade without concern for loss of the desired activity.

    摘要翻译: 本发明涉及薄膜产品包含活性组分和它们的制备方法的期望水平。 期望地,膜崩解于水中,可通过受控的干燥过程中形成,或者其他processthat保持膜的所需均匀性。 期望地,膜可以暴露于温度高于没有在其中的活性成分通常不降解为所需的活性的损失的关注。

    THIN FILM WITH NON-SELF-AGGREGATING UNIFORM HETEROGENEITY, PROCESS FOR THER PRODUCTION AND DRUG DELIVERY SYSTEMS MADE THEREFROM
    7.
    发明公开
    THIN FILM WITH NON-SELF-AGGREGATING UNIFORM HETEROGENEITY, PROCESS FOR THER PRODUCTION AND DRUG DELIVERY SYSTEMS MADE THEREFROM 审中-公开
    薄膜不与均匀多相性,方法及其SELBTAGGREGATION及由其制成的药物输送系统

    公开(公告)号:EP2351557A1

    公开(公告)日:2011-08-03

    申请号:EP10182204.7

    申请日:2002-10-11

    申请人: MonoSol RX LLC

    IPC分类号: A61K9/70 A61K9/00

    摘要: The invention relates to the film products and methods of their preparation that demonstrate a non-self-aggregating uniform heterogeneity. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. Desirably, the films contain a pharmaceutical and/or cosmetic active agent with no more than a 10% variance of the active agent pharmaceutical and/or cosmetic active agent per unit area of the film.

    摘要翻译: 本发明涉及的膜产品和它们的制备方法都展示出一种非自聚集的均匀异质性。 期望地,膜崩解于水中,可通过受控的干燥过程中形成,或者其他processthat保持膜的所需均匀性。 理想地,该膜含有的药物和/或美容活性剂与不超过膜每单位面积的活性剂的药物和/或美容活性剂的10%的变化更多。